Jean-Pierre Delord Selected Research

imgatuzumab

2/2014	Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma.
10/2011	Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jean-Pierre Delord Research Topics

Disease

64	Neoplasms (Cancer) 06/2022 - 06/2006
11	Squamous Cell Carcinoma of Head and Neck 01/2021 - 12/2007
10	Carcinoma (Carcinomatosis) 01/2022 - 09/2010
9	Disease Progression 01/2022 - 03/2012
9	Colorectal Neoplasms (Colorectal Cancer) 12/2020 - 02/2003
7	Melanoma (Melanoma, Malignant) 01/2021 - 12/2015
7	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2020 - 03/2008
7	Breast Neoplasms (Breast Cancer) 01/2020 - 08/2007
6	Asthenia 01/2021 - 11/2011
6	Ovarian Neoplasms (Ovarian Cancer) 07/2020 - 01/2014
6	Head and Neck Neoplasms (Head and Neck Cancer) 01/2020 - 09/2010
5	Fatigue 01/2022 - 06/2012
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 05/2013
4	Neoplasm Metastasis (Metastasis) 01/2022 - 06/2015
4	Diarrhea 01/2021 - 11/2011
4	Febrile Neutropenia 12/2020 - 10/2013
3	Exanthema (Rash) 01/2022 - 12/2018
3	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 12/2020 - 01/2017
3	Mesothelioma 11/2020 - 01/2019
2	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 10/2018
2	Edema (Dropsy) 01/2021 - 10/2020
2	Hypotension (Low Blood Pressure) 11/2020 - 10/2013
2	Thrombocytopenia (Thrombopenia) 12/2018 - 10/2018
2	Nausea 10/2018 - 11/2011
2	Hyperglycemia 08/2018 - 11/2011
2	Constipation 01/2018 - 06/2012
2	Hyperphosphatemia 01/2018 - 01/2017
2	Thyroid Neoplasms (Thyroid Cancer) 01/2017 - 01/2010
1	Hepatocellular Carcinoma (Hepatoma) 06/2022
1	Ewing Sarcoma (Sarcoma, Ewing) 01/2022
1	Carcinogenesis 01/2022

Drug/Important Bio-Agent (IBA)

11	Cetuximab (Erbitux)FDA Link 01/2021 - 06/2006
9	pembrolizumabIBA 01/2022 - 01/2018
9	Monoclonal AntibodiesIBA 01/2022 - 06/2006
8	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 02/2009
7	Pharmaceutical PreparationsIBA 01/2021 - 06/2012
6	Biomarkers (Surrogate Marker)IBA 06/2022 - 09/2010
6	PlatinumIBA 01/2021 - 03/2008
5	Immune Checkpoint InhibitorsIBA 01/2022 - 12/2015
5	LigandsIBA 01/2022 - 01/2018
5	Proteins (Proteins, Gene)FDA Link 02/2021 - 09/2010
5	Fluorouracil (Carac)FDA LinkGeneric 01/2021 - 02/2003
5	ErbB Receptors (EGF Receptor)IBA 12/2020 - 06/2006
5	Erlotinib Hydrochloride (CP 358,774)FDA Link 06/2013 - 12/2007
4	Irinotecan (Camptosar)FDA LinkGeneric 01/2022 - 01/2011
4	emactuzumabIBA 01/2022 - 06/2014
4	NivolumabIBA 01/2021 - 11/2019
4	CreatinineIBA 12/2020 - 01/2018
3	atezolizumabIBA 01/2022 - 01/2019
3	PM 01183IBA 01/2022 - 01/2020
3	B7-H1 AntigenIBA 01/2021 - 10/2019
3	Docetaxel (Taxotere)FDA Link 01/2021 - 01/2017
3	AntibodiesIBA 01/2020 - 01/2019
3	AfatinibIBA 12/2018 - 01/2018
3	Trastuzumab (Herceptin)FDA Link 12/2018 - 06/2011
3	Vinorelbine (Navelbine)FDA LinkGeneric 01/2018 - 02/2009
3	Tyrosine Kinase InhibitorsIBA 01/2017 - 02/2015
3	Antineoplastic Agents (Antineoplastics)IBA 01/2016 - 05/2013
3	Oxaliplatin (Eloxatin)FDA LinkGeneric 03/2012 - 02/2003
2	spartalizumabIBA 06/2022 - 10/2020
2	Oncogene Proteins (Oncogene Protein)IBA 01/2022 - 01/2016
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 02/2021 - 01/2021
2	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 02/2021 - 01/2021
2	AcidsIBA 02/2021 - 02/2003
2	Tumor Necrosis Factor InhibitorsIBA 01/2021 - 11/2019
2	N- (2,3- dihydroxypropyl)- 1- ((2- fluoro- 4- iodophenyl)amino)isonicotinamideIBA 01/2021 - 01/2021
2	Infliximab (Remicade)FDA Link 01/2021 - 11/2019
2	CytokinesIBA 01/2021 - 03/2014
2	Inhibitor of Apoptosis ProteinsIBA 12/2020 - 01/2020
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 12/2020 - 10/2020
2	Alanine Transaminase (SGPT)IBA 12/2020 - 07/2011
2	Macrophage Colony-Stimulating FactorIBA 10/2020 - 08/2015
2	Carboplatin (JM8)FDA LinkGeneric 01/2020 - 01/2016
2	durvalumabIBA 01/2020 - 01/2019
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2020 - 11/2019
2	F14512IBA 01/2019 - 01/2016
2	PolyaminesIBA 01/2019 - 01/2016
2	Pemetrexed (MTA)FDA Link 01/2019 - 01/2017
2	Gemcitabine FDA Link 12/2018 - 05/2015
2	OTX015IBA 10/2018 - 01/2016
2	AlpelisibIBA 08/2018 - 01/2017
2	infigratinibIBA 01/2018 - 01/2017
2	Type 1 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 1)IBA 01/2018 - 01/2017
2	Phosphotransferases (Kinase)IBA 09/2017 - 01/2017
2	encorafenibIBA 09/2017 - 01/2017
2	Sunitinib (Sutent)FDA Link 01/2017 - 01/2010
2	Protein Isoforms (Isoforms)IBA 06/2015 - 01/2011
2	imgatuzumabIBA 02/2014 - 10/2011
2	vinflunineIBA 06/2012 - 03/2008
1	roblitinibIBA 06/2022
1	Transcription Factors (Transcription Factor)IBA 01/2022
1	Viral DNAIBA 01/2022

Therapy/Procedure

28	Therapeutics 01/2022 - 08/2007
16	Drug Therapy (Chemotherapy) 01/2022 - 08/2007
6	Chemoradiotherapy 01/2022 - 01/2018
6	Immunotherapy 01/2022 - 05/2014
3	Radiotherapy 05/2019 - 12/2015
2	Intravenous Infusions 01/2020 - 01/2020
2	Aftercare (After-Treatment) 06/2013 - 11/2011
2	Combination Drug Therapy (Combination Chemotherapy) 01/2011 - 02/2009